Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $1.85B.
ENTERPRISE VALUE (EV)
$1.85B
Trevi Therapeutics, Inc.
Market Cap
$1.87B
Enterprise Value (EV)
$1.85B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.87B | $1.85B |
| Novavax, Inc. (NVAX)vs › | $1.86B | $1.97B |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | $1.88B |
| Zymeworks Inc. (ZYME)vs › | $1.89B | $1.98B |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | $1.83B |
| Immunome, Inc. (IMNM)vs › | $1.85B | $1.63B |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | $1.65B |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | $2.41B |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | $2.30B |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | $2.11B |
Market Cap
$1.87B
Total Debt
$0.00
Cash
$18.91M
Enterprise Value
$1.85B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
